Given the goal of this study to measure the effect of rapamycin on pre-existing colon cancers with a dominantly active PI3K, we placed into our therapeutic study 22 FC PIK3ca* mice at 55 days of age, an age when most have pre-existing cancer, but have not yet become moribund. Here, PIK3CA is linked to colonic neoplasm.